DAIICHI SANKYO, INC.
- Country
- π―π΅Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
- Conditions
- Advanced Hepatocellular CarcinomaLiver CancerHepatic CancerLiver Neoplasms
- Interventions
- Drug: CS-1008 2 mg/kgDrug: CS-1008 4 mg/kgDrug: CS-1008 6 mg/kgDrug: CS-1008 6/2 mg/kgDrug: CS-1008 6/6 mg/kg
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 172
- Registration Number
- NCT01033240
- Locations
- πΊπΈ
Kenmar Research Group, Los Angeles, California, United States
πΊπΈGeorgetown-Lombardi Cancer Center, Washington, District of Columbia, United States
πΊπΈThe Mount Sinai Medical Center, New York, New York, United States
Prasugrel/Clopidogrel Maintenance Dose Washout Study
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 56
- Registration Number
- NCT01014624
- Locations
- πΊπΈ
Scripps Clinic, La Jolla, California, United States
πΊπΈUniversity of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States
πΊπΈMedpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Safety Study of PLX108-01 in Patients With Solid Tumors
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 132
- Registration Number
- NCT01004861
- Locations
- πΊπΈ
HonorHealth, Scottsdale, Arizona, United States
πΊπΈUCLA, Los Angeles, California, United States
πΊπΈRocky Mountain Cancer Centers, Denver, Colorado, United States
CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naΓ―ve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 109
- Registration Number
- NCT00991796
- Locations
- π©πͺ
Asklepios Fachkliniken Munchen Gauting, Gauting, Germany
π©πͺZentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Compound AC220
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 333
- Registration Number
- NCT00989261
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
πΊπΈNorthwestern Memorial Hospital, Chicago, Illinois, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 84
- Registration Number
- NCT00986440
- Locations
- π¨πΏ
Fakulti nemocnice Brno, Brno, Czechia
π¨πΏFakultni nemocnice Olomouc, Olomouc, Czechia
π¨πΏNemocnice Znojmo, p.o., Oddeleni radiacni a klinicke onkologie, Znojmo, Czechia
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
- Conditions
- Pulmonary Embolism (PE)Venous ThromboembolismThromboembolismDeep Vein Thrombosis (DVT)Venous Thrombosis
- Interventions
- Drug: low molecular weight heparin/unfractionated heparin
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8292
- Registration Number
- NCT00986154
- Locations
- πΊπΈ
Investigational Site 7103, Mobile, Alabama, United States
πΊπΈInvestigational Site 7132, Montgomery, Alabama, United States
πΊπΈInvestigational Site 7126, Phoenix, Arizona, United States
CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8
- Registration Number
- NCT00969033
- Locations
- π¬π§
Broomfield Hospital, Chelmsford, Essex, United Kingdom
π¬π§Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
π¬π§Nottingham City Hospital, Nottingham, Notts, United Kingdom
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
- Conditions
- Neoplasms, ColorectalColorectal Cancer
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 100
- Registration Number
- NCT00967616
- Locations
- πΊπΈ
Beverly Hills Cancer Center, Beverly Hills, California, United States
πΊπΈSt. Jude Heritage Medical Group, Fullerton, California, United States
πΊπΈJohn Marshall, Washington, District of Columbia, United States
Olmesartan Comparison to Losartan in Hypertensive Subjects
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 941
- Registration Number
- NCT00949884